Epiminder CEO Rohan Hoare outlines DETECT trial progress, FDA age expansion, and 2028 commercial launch plans
Summary
Epiminder CEO Rohan Hoare discusses the company's objective to replace subjective seizure diaries with implantable EEG monitoring for drug-resistant epilepsy. He highlights that the DETECT post-market reimbursement trial has enrolled 100 participants across 23 centers, with full enrollment targeted for H1 2027. Hoare notes FDA clearance has expanded the MINDAR device's age indication to 12-75 years and cites an Australian study where EEG data informed clinical decisions 88% of the time. Financially, the company holds over $65 million in cash, supporting development of a next-generation slimline device and early revenue proof points. The commercial launch is targeted for early 2028, prioritizing the US market before expanding to Australia and globally.
Key takeaways
- 1 In the study we conducted in Australia, which were used for FDA approval, the EEG monitoring informed clinical decision making 88% of the time.
Unidentified speaker (speaker_1) · 0:55
- 2 Company holds over $65 million in cash as of September quarter Appendix 4C report.
Unidentified speaker (speaker_0) · 3:16
- 3 Next-generation slimline MINDAR device targets completion in H1 2027.
Unidentified speaker (speaker_1) · 3:52
- 4 Commercial launch is targeted for the beginning of calendar 2028.
Unidentified speaker (speaker_1) · 4:52
Episode sections
- 0:04 – 0:55
Introduction and Company Overview
Host introduces Epiminder Limited (ASX:EPI) and CEO Rohan Hoare. Hoare describes the goal to replace subjective seizure diaries with objective, long-term EEG monitoring for drug-resistant epilepsy, comparing the technology to continuous glucose monitors.
- 0:55 – 1:17
Technology and Clinical Validation
Hoare details the Epiminder system: an implantable EEG under the scalp, a wearable, a companion phone, and a cloud app. He cites an Australian study used for FDA approval where EEG monitoring informed clinical decision-making 88% of the time.
- 1:17 – 2:04
DETECT Trial Progress
The host notes the DETECT post-market reimbursement trial has enrolled its 100th participant ahead of schedule. Hoare confirms the enrollment across 23 centers, including Harvard, Stanford, Yale, UPenn, and Mayo, indicating strong clinician and patient acceptance.
- 2:04 – 2:35
2026-2027 Milestones
Hoare outlines that the 125th patient enrollment is targeted for December, with full enrollment expected in the first half of calendar 2027. Following enrollment, a six-month control period will precede the data readout phase.
- 2:35 – 3:16
FDA Age Expansion
The host asks about FDA clearance expanding the MINDAR device's indicated age range from 18+ to 12-75 years. Hoare explains this helps clinicians manage epilepsy during the critical developmental and educational years of adolescence.
- 3:16 – 4:13
Financial Position and Strategic Priorities
Hoare cites the September quarter Appendix 4C report, noting over $65 million in cash. He outlines four priorities: completing the DETECT trial, developing a next-generation slimline device (targeted for H1 2027), establishing early revenue proof points, and developing the go-to-market model.
- 4:13 – 5:09
Revenue Streams and Commercial Launch
Hoare identifies potential revenue sources including the US Veterans Administration, Medicare, pharmaceutical companies, and the Australian SAS scheme. He states the goal is a commercial launch at the beginning of calendar 2028, supported by clinical data and a proven market access plan.
- 5:09 – 6:34
Global Expansion Strategy
Hoare identifies the US as the primary initial market, followed by Australia (where the device is designed and manufactured), and then broader global expansion. He emphasizes the need for success in early markets to facilitate wider adoption.
Claims worth verifying
Epiminder Limited is a medical device and digital health company focused on improving epilepsy care through continuous long-term brain activity monitoring.
Unidentified speaker (speaker_0) ·0:04
How to verify: Company website (epiminder.com) and ASX announcements for Epiminder Ltd (ASX:EPI). For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
EEG monitoring informed clinical decision making 88% of the time in an Australian study used for FDA approval.
Unidentified speaker (speaker_1) ·0:55
How to verify: FDA 510(k) summary or De Novo classification summary for Epiminder's MINDAR device, specifically looking for the clinical study referenced in the submission. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
The DETECT post-market reimbursement trial has enrolled its 100th participant ahead of schedule across 23 centers.
Unidentified speaker (UNKNOWN) ·1:30
How to verify: ClinicalTrials.gov record for the DETECT study (NCT number to be identified in Epiminder filings) and recent ASX media releases from Epiminder Ltd. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Primary sourceParticipating centers include Harvard, Stanford, Yale, UPenn, and Mayo.
Unidentified speaker (UNKNOWN) ·1:30
How to verify: ASX media releases from Epiminder Ltd detailing the DETECT trial sites. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
The 125th milestone patient enrollment should be by December.
Unidentified speaker (speaker_1) ·2:11
How to verify: ASX media releases from Epiminder Ltd regarding DETECT trial milestones. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Full enrollment is on track for the first half of calendar 2027.
Unidentified speaker (speaker_1) ·2:11
How to verify: ASX media releases from Epiminder Ltd regarding DETECT trial timelines. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
FDA clearance expanded MINDAR's indicated age range to patients aged 12 and older.
Unidentified speaker (speaker_0) ·2:35
How to verify: FDA 510(k) or De Novo decision letter for Epiminder's MINDAR device. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
The company closed the September quarter with over $65 million in cash and cash equivalents.
Unidentified speaker (speaker_0) ·3:16
How to verify: Epiminder Ltd September 2026 Quarterly Cash Report (Appendix 4C) filed with ASIC. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
The next generation MINDAR device is on track for completion by the end of the first half of calendar 2027.
Unidentified speaker (speaker_1) ·3:52
How to verify: ASX media releases from Epiminder Ltd regarding product development milestones. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Epilepsy affects over 50 million people globally.
Unidentified speaker (speaker_0) ·5:09
How to verify: World Health Organization (WHO) or Epilepsy Foundation global prevalence statistics. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the 88% clinical decision-making statistic by reviewing the specific Australian study cited for FDA approval.
- Check the ASX announcement or Appendix 4C for the exact cash balance and burn rate as of the September quarter.
- Review the DETECT trial protocol and current enrollment status on ClinicalTrials.gov to confirm the 100-patient milestone and 23-center count.
- Assess the regulatory pathway for the next-generation slimline device and its impact on COGS and margins.
- Investigate the specific reimbursement criteria for Medicare and the US Veterans Administration for implantable EEG devices.
- Confirm the timeline for the six-month control period and subsequent data readout post-enrollment.
- Evaluate the competitive landscape for continuous EEG monitoring in the epilepsy market.
- Review the company's cash runway analysis to ensure sustainability through the 2028 launch target.
Full transcriptexpand
- 0:04
- Unidentified speaker (speaker_0): Welcome to another episode of ASX Briefs. And today I'm joined by Rowan Hoare, the CEO of Epiminder Limited, a medical device and digital health company focused on improving epilepsy care through continuous long-term brain activity monitoring. Rowan, great to have you with me today and welcome to the ASX Briefs podcast.
- 0:23
- Unidentified speaker (speaker_1): Very nice to be here, Andrew.
- 0:24
- Unidentified speaker (UNKNOWN): Yeah, Now
- 0:25
- Unidentified speaker (speaker_0): Rowan, you've just released your quarterly results. but before we get into that, can you just give our listeners a quick overview of the company?
- 0:31
- Unidentified speaker (speaker_1): Absolutely. Epiminder is looking to establish a new standard of care for drug-resistant epilepsy, moving from very subjective diaries to objective seizure monitoring over periods of months to years. The concept of of long-term monitoring is very similar to what people are probably familiar with, continuous glucose monitors or cardiac monitors.
- 0:51
- Unidentified speaker (speaker_1): which really transformed diabetes and cardiology care.
- 0:55
- Unidentified speaker (speaker_1): In the study we conducted in Australia, which were used for FDA approval, the EEG monitoring informed clinical decision making 88% of the time. And so we think this has got a real application in the epilepsy space. The technology consists of an implant under the scalp, a wearable, a companion phone, and a cloud app, and it's the first of its good off.
- 1:14
- Unidentified speaker (speaker_1): authorized by the FDA.
- 1:16
- Unidentified speaker (UNKNOWN): Now
- 1:17
- Unidentified speaker (speaker_0): let's dive into the recent operational and clinical updates. The company has just crossed a major milestone enrolling their 100th participant in your US detect study ahead of schedule. Tell us what's driving the enrollment momentum.
- 1:30
- Unidentified speaker (UNKNOWN): Yeah,
- 1:30
- Unidentified speaker (speaker_1): we're very pleased, Andrew, with the Detect uh postmarket reimbursement trial progress. We've assembled an A list of uh centers participating, 23 at uh present Capitol. count, including Harvard, Stanford, Yale, UPen, Mayo, and many others. With the study more than halfway enrolled, it's clear that clinicians are proposing and patients are accepting of them the MINDAR as the next step in
- 1:50
- Unidentified speaker (speaker_1): their clinical care. The trial is a randomized clinical trial though. So I don't have specific insight into the trial results, but one would anticipate that the MINDAR Minder is providing clinical insights and that's why there's momentum uh
- 2:03
- Unidentified speaker (UNKNOWN): And
- 2:04
- Unidentified speaker (speaker_0): you touched on being past that halfway point. So what are the key milestones we should be watching out for for the remainder of 26 and into 2027?
- 2:11
- Unidentified speaker (speaker_1): Yeah, we don't have much of 26 uh left, that's for sure. But we should be looking uh for uh continued enrollment milestones. We put out there that the 125th milestone patient enrollment should be by December, and that we are on track for full enrollment by the first half of calendar 2026. 2027. I think those are sort of the enrollment milestones. And then once we've got it enrolled,
- 2:31
- Unidentified speaker (speaker_1): it would be a readout phase after a six-month control period.
- 2:35
- Unidentified speaker (speaker_0): And you have just received US FDA clearance to expand MINDAR's indicated age range from adults aged 18 and older to patients aged 12 and older with drug-resistant drug resistant epilepsy. What does this clearance mean for every EpiMinder minder and the patients who now can access the technology?
- 2:51
- Unidentified speaker (speaker_1): Yeah, we're really pleased with the expansion of the indication to a population between 12 and 75 years of age. You know, all of us probably remember that adolescence is a difficult time and epilepsy can certainly make that more difficult. And think having minder device indicated for this population can really help clinicians and patients navigate the developmental,
- 3:11
- Unidentified speaker (speaker_1): educational and growth of independence during these formative years.
- 3:15
- Unidentified speaker (UNKNOWN): And
- 3:16
- Unidentified speaker (speaker_0): looking at your financials now, the company has just released its appendix 4C for the September quarter and is in a strong financial position, closing out the quarter with over $65 million in cash and cash equivalents. How does that funding position support the company's priorities over the next 12 to 18 months?
- 3:32
- Unidentified speaker (speaker_1): Yeah, I think we're in a very good cash position. We have the resources to fund our our four main priorities over the next 12. to 18 months, and I'll just go over them. The first is uh the enrollment and the detect trial. As we said, we're more than halfway done and anticipate having that completed by the enrollment by the first half of calendar twenty-seven. Second, thrust is around the
- 3:52
- Unidentified speaker (speaker_1): next generation minder device. This is a slimline technology with technology forward components and really designed design for manufacturability. It brings uh a number of benefits. for clinicians, patients, and obviously lower cogs for an improved PL. And that is on track for completion by the end of the first half of calendar 27 as well.
- 4:13
- Unidentified speaker (speaker_1): The third initiative is around establishing early revenue proof points in the in the market, where we navigate the sales processes in a number of different market segments, including the Veterans Administration, U.S. Medicare patient populations. pharmaceutical companies, and then back in Oz with the Australian SAS scheme. So really looking to
- 4:32
- Unidentified speaker (speaker_1): show that we can penetrate the market with the technology. And then the last is really sort of developing the go-to-market model. The detect program is really providing us valuable insight into how clinicians are utilizing the technology and how they're starting to embed uh the monitor mind or in their clinical practice. So pulling those four uh to together really sets us up for the
- 4:52
- Unidentified speaker (speaker_1): commercial launch at the beginning of calendar 28. So we have
- 4:56
- Unidentified speaker (speaker_1): the clinical and reimbursement data. We have the product we want to take to market. We have then at that point a proven way to access the market and they go to market plan. And I think that's really sort of an incredibly exciting period for us.
- 5:09
- Unidentified speaker (speaker_0): Taking a back review now, epilepsy affects over 50 million people globally. So where do you see the beginning? biggest opportunity for MINADA and what needs to happen to drive broader clinical adoption?
- 5:19
- Unidentified speaker (speaker_1): Yep. Uh so epilepsy is a global disease. Our best opportunity to be able to offer the MINADE to the world is being actually successful in the uh target markets uh when we launch. And that will be first the US, and then we have uh plans to bring that back home to Australia once we've completed the next generation device. After all it's an Australian
- 5:39
- Unidentified speaker (speaker_1): uh designed and manufactured technology, Australians should have access to it. After that, we'll be looking at sort of uh taking this more broadly, but I I firmly believe you've got to be successful in the early markets that you that you tackle in order to be able to sort of spread it further.
- 5:53
- Unidentified speaker (UNKNOWN): Now,
- 5:53
- Unidentified speaker (speaker_0): Rao, and just to wrap things up, what's the single key message you'd like to leave with our listeners and shareholders today?
- 5:58
- Unidentified speaker (speaker_1): I would say uh just a little bit about epilepsy. It's the second most common seriousness serious neurological disease affecting some fifty million people worldwide. Epiminder is seeking to establish a new standard of monitoring, improving clinical decision making and improving patients' lives.
- 6:13
- Unidentified speaker (UNKNOWN): Okay,
- 6:14
- Unidentified speaker (speaker_0): Rowan. Well, it's been great to have you on the podcast today. So thanks for your time, and we look forward to further updates from Epiminder through 2027.
- 6:21
- Unidentified speaker (UNKNOWN): Thank
- 6:21
- Unidentified speaker (speaker_1): you very much, Andrew.
- 6:22
- Unidentified speaker (UNKNOWN): That
- 6:23
- Unidentified speaker (speaker_0): concludes this episode of ASX Briefs. Don't forget to subscribe. and we look forward to catching you on our next episode.
More from ASX BRIEFS
NICKEL INDUSTRIES LTD (ASX:NIC) - Nickel Profits In Indonesia
Episode discussion: Nickel Industries reports strong Q3 2026 results driven by mining volume growth and ENC commissioning milestones.
Speakers’ claims: Nickel Industries (ASX:NIC) reported a group adjusted EBITDA exceeding US$125 million for the September 2026 quarter, driven by a 56% increase in sales volume to 4.5 million wet metric tons. Mining operations contributed US$76.9 million in adjusted EBITDA, with margins exceeding $17 per ton. The company highlighted commissioning progress at the Excelsior Nickel Cobalt (ENC) project, including first MHP and nickel cathode production, and secured an MHP export exemption. Management announced a US$245 million project finance facility at approximately 5.7% interest to recapitalize shareholders. Operational challenges were cited due to severe El Niño-induced water shortages, with October rainfall at 7mm versus a historical average of 500mm. Additionally, the company described a stake swap valuing its Sampala project at approximately US$1.3 billion.
SENSEN NETWORKS LTD (ASX:SNS) - How Councils Use Cameras And Sensors To Automate Street Work
Episode discussion: Sensen Networks reports record Q1 cash receipts and expanding physical AI platform for municipal automation.
Speakers’ claims: CEO Subash Challah describes Sensen Networks as a physical AI company that automates street monitoring for city councils using camera and sensor data. The company reported record Q1 cash receipts of $5.3 million, a 23% year-over-year increase, driven by a sticky customer base with near-zero churn. Annual Recurring Revenue (ARR) reached a record $12 million, up 17%, fueled by both new client acquisitions and expanded usage among existing customers. Challah highlighted the company's operational discipline, noting quarterly cash flow positivity for most of the last eight quarters without external capital raises. The platform is expanding into adjacent use cases such as noise monitoring and illegal dumping management, with recent wins in North America and India.